Loading
DNA Repair Mechanisms · Journal article
Microbiology Spectrum · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic and exploratory study demonstrating that mitoxantrone, an anticancer agent, shows in vitro synergy with tigecycline against K. pneumoniae via enhanced intracellular accumulation, and exhibits efficacy in a murine wound infection model. The work is hypothesis-generating and does not provide evidence sufficient to recommend clinical use; human efficacy and safety trials would be required.
Mechanistic and exploratory in vitro and in vivo study. K. pneumoniae bacterial strains and mice with wound infections; no human subjects enrolled. Intervention: Mitoxantrone alone and in combination with tigecycline. Compared with: Tigecycline alone; untreated controls implied but not explicitly stated.
Mitoxantrone resistance arises via mutations in kstR2 gene leading to SmvA efflux pump overexpression Mitoxantrone induces bacterial SOS response, consistent with DNA damage mechanism Mitoxantrone exhibits synergistic effect with tigecycline against K. pneumoniae both in vitro and in murine wound infection model
No toxicity or safety data for mitoxantrone as an antimicrobial in this context
This work identifies a potential drug repurposing strategy but is preclinical. Clinicians should not consider mitoxantrone for K. pneumoniae treatment outside investigational protocols until human efficacy and safety are established.
Mechanistic and proof-of-concept work in vitro and in a murine model identifying a drug repurposing opportunity; lacks human efficacy data and clinical validation needed to support practice change.
As stated by the source record.
This work identifies a potential drug repurposing strategy but is preclinical. Clinicians should not consider mitoxantrone for K. pneumoniae treatment outside investigational protocols until human efficacy and safety are established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT The global health threat of antimicrobial resistance necessitates the development of novel therapeutic strategies. This study identifies the anticancer agent mitoxantrone as a potent antimicrobial against Klebsiella pneumoniae. Through passaging experiments, we demonstrate that resistance to mitoxantrone arises via mutations in the kstR2 gene, leading to the overexpression of the SmvA efflux pump. Transcriptomic analysis reveals that mitoxantrone treatment induces the bacterial SOS response, likely due to DNA damage. Critically, we found that mitoxantrone exhibits a synergistic effect with tigecycline against K. pneumoniae, both in vitro and in a murine wound infection model. Mechanistically, this synergy is driven by tigecycline-mediated enhancement of intracellular mitoxantrone accumulation. These findings reveal a potentially effective combination regimen to combat K. pneumoniae infections. IMPORTANCE The rise of antibiotic-resistant Klebsiella pneumoniae demands new treatment options. This study uncovers that mitoxantrone, a drug currently approved for cancer therapy, is effective against K. pneumoniae. Furthermore, we discovered that combining mitoxantrone with the existing antibiotic tigecycline is synergistic against K. pneumoniae. We found that tigecycline enhances mitoxantrone accumulation inside bacterial cells. Overall, our work identified the tigecycline-mitoxantrone combination as a promising strategy to treat K. pneumoniae infections.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.